CLN Article

Grail Enlists Mayo Clinic, Sutter Health to Develop Early-Stage Cancer Tests

Industry Playbook: June 2017

Mayo Clinic and Sutter Health have teamed with new life sciences company Grail to develop genomic blood tests for early-stage cancer diagnosis. A spinoff of Illumina, Grail is headed by former Google senior vice president Jeff Huber and has received more than $100 million of funding from Google, Bill Gates, Jeff Bezos, and other venture capitalists to pursue its mission of enabling cancer detection in the disease’s initial, curable stages. Grail has now launched its second multi-center clinical study, known as STRIVE, to train and validate a blood test to detect breast cancer. This longitudinal, prospective observational study will enroll up to 120,000 women at Mayo Clinic and throughout the Sutter Health system, and will collect baseline blood samples from participants at the time of their screening mammograms. Grail will also use the STRIVE study to develop a pan-cancer test to detect multiple cancers at early stages.

Advertisement
Advertisement